Wengang Li

Xidian University — China

Medicine · Health Sciences

35h-index5.2kcitations258works7.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis(29), Liver Disease Diagnosis and Treatment(22), Cholangiocarcinoma and Gallbladder Cancer Studies(21), Sarcoma Diagnosis and Treatment(16), Liver Disease and Transplantation(12)

Publications254 total

Hepatocyte‐Derived Extracellular Vesicles Deliver miR‐328‐3p to Trigger PP2A‐B56δ–Mediated p‐NLRP3 <sup>S295</sup> ‐Dependent Metaflammation in Macrophages upon Microcystin‐LR Exposure
Advanced Science·2025· 2 citedOpen Access
Integrating machine learning and molecular dynamics simulation to decipher the molecular network of dioxin-associated liposarcoma
Scientific Reports·2025Open Access
Extracellular Vesicles in Sarcoma: Implications for Tumor Progression and Therapy
International Journal of Nanomedicine·2025Open Access
A rare case report: retroperitoneal dedifferentiated liposarcoma associated with paraneoplastic pemphigus
Frontiers in Surgery·2025· 1 citedOpen Access
Performance evaluation of multi-shell LEO satellite constellations in 6G communication systems
Journal of Information and Intelligence·2025Open Access
<i>MALAT1</i> promotes malignancy of HBV-related hepatocellular carcinoma by regulating IGF2BP3-mediated nuclear-cytoplasmic shuttling
International Journal of Biological Sciences·2025· 4 citedOpen Access
Three-dimensional characterization of autoignition kernel development under varied jet velocity and coflow temperature conditions
Physics of Fluids·2025
Genetically engineered GSDME vesicle coated nanoparticle for immune activating and pyroptosis inducing synergetic therapy of fibrosarcoma
Materials Today Bio·2025· 1 citedOpen Access
Biomimetic Hybrid Membrane-Cloaked Nanoparticles Assisted with Laser Irradiation for Synergistic Photothermal Immunotherapy of Fibrosarcoma
ACS Applied Nano Materials·2025· 1 cited
Combination of immune checkpoint inhibitors and anthracyclines as a potential first-line regimen for dedifferentiated liposarcoma: systematic review and meta-analysis
Cancer Immunology Immunotherapy·2025· 1 citedOpen Access
Current status and future perspectives of immunotherapy for abdominal liposarcoma: From basic research to clinical practice
World Chinese Journal of Digestology·2025Open Access
Tumor Microenvironment-Responsive Nanodrug for Embolotherapy and Enhanced Chemotherapy
ACS Applied Materials & Interfaces·2025· 3 cited
Chinese Guidelines on the Management of Hepatic Encephalopathy in Cirrhosis (2024)
Journal of Clinical and Translational Hepatology·2025· 4 citedOpen Access
Immunotherapy as a Potential First-Line Regimen for Dedifferentiated Liposarcoma: A Meta-Analysis
2025Open Access
Ligand-Targeted Ag<sub>9</sub> Cluster Self-Cascade Antioxidants for Enhanced Reactive Oxygen Species Clearance in the Treatment of Inflammatory Bowel Disease
Nano Letters·2025· 6 cited
Baseline <scp>FIB</scp> ‐4 May Be a Risk Factor of Recurrence After <scp>SBRT</scp> in Patients With <scp>HBV</scp> ‐Related Small <scp>HCC</scp>
Cancer Medicine·2025· 1 citedOpen Access
Prognostic significance of early alpha fetoprotein and des-gamma carboxy prothrombin responses in unresectable hepatocellular carcinoma patients undergoing triple combination therapy
Frontiers in Immunology·2024· 3 citedOpen Access
Radiofrequency Ablation Therapy versus Stereotactic Body Radiation Therapy for Naive Hepatocellular Carcinoma (≤5cm): A Retrospective Multi-Center Study
Journal of Hepatocellular Carcinoma·2024· 5 citedOpen Access
Intraoperative radiotherapy might not serve as a standard therapy for retroperitoneal liposarcoma: insights from a population-based propensity score-matched study
Frontiers in Oncology·2024· 2 citedOpen Access
Exploring the common targets of well-differentiated and dedifferentiated retroperitoneal liposarcoma via gene co-expression analysis
Heliyon·2024Open Access
page 1 of 13Next →

Frequent Co-authors

Chundong Yu(10), Pingli Mo(8), Kesong Peng(5), Ming Li(5), Xiaoyuan Xu(5), Zhongping Duan(4), Jidong Jia(4), Hui Zhuang(4), Qiang Chen(4), Yue Kong(3), Qu Shen(3), Chengchao Chu(3), Gang Liu(3), Hu Zhou(3), Tingdong Yan(3), Xihua Cao(3), Jin-Zhang Zeng(3), Huiguo Ding(3), Lai Wei(3), Enqiang Linghu(3)